Physician profile
Autumn Hirrill
NPI 1790268589
$2,307.84
in general payments reported to CMS, 2019-2025
18 companies · $1,588 in 2025
The $1,588 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $720 · 2025: $1,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,307.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $375.52 | 2024-2025 | Onyda Xr, Dyanavel Xr |
| Abbvie INC. | $333.91 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $299.19 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $298.28 | 2024-2025 | Auvelity |
| Lundbeck LLC | $166.82 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $165.61 | 2025 | Trintellix |
| Saluda Medical Americas, INC. | $144.23 | 2024 | Evoke |
| Corium, LLC | $107.62 | 2024-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $101.19 | 2024-2025 | Xtampza, Belbuca, Jornay Pm |
| Supernus Pharmaceuticals, INC. | $56.79 | 2025 | Qelbree |
| Neurocrine Biosciences, INC. | $56.13 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.41 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $41.10 | 2025 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $32.67 | 2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.73 | 2024 | Relistor |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $21.07 | 2025 | Aristada, Lybalvi |
| Tempus Ai, INC | $17.45 | 2024 | Tempus Pixel |
| Vanda Pharmaceuticals INC. | $17.12 | 2025 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Autumn Hirrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.